Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medicenna Therapeutics Corp. T.MDNA

Alternate Symbol(s):  MDNA

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the...

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

Medicenna (TSX:MDNA) drug stimulates anti-cancer response

https://themarketherald.ca/medicenna-announces-new-clinical-data-showing-dose-dependent-stimulation-of-anti-cancer-immune-cells-with-mdna11-in-the-phase-1-2-ability-study-2022-05-02/  rate and reply

PR

Good News. Not sure what the market is waiting for ?!  rate and reply

Peer-Reviewed Publication of Preclinical Data on MDNA11

MDNA11 demonstrates a 30-fold increase in affinity for IL-2 receptor beta without binding to IL-2 receptor alpha when compared to recombinant human IL-2 -- MDNA11 was well-tolerated and induced...read more

mdna 52 week high very possible, very soon

$mdna 52 week high of $6.82. If it was done once, it can be done again, esp with big catalyst in less than one month!  rate and reply

mdna 55 deal

This would be huge: Resesarch Capital Analyst Uddin believes efforts to secure deal for $MDNA 55 prior to start of Phase 3 clinical trial will serve as key catalyst, as he made the assumption of a...read more

Research Capital price target of $6.90

$mdna   Canadian biotech company Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News TSX:MDNA) has lost a lot of ground in 2021 but analyst Andre Uddin of Research Capital...read more

MDNA is a swing trade now! let's go!

$mdna big swing trading play... mdna will report data on their lead drug program (mdna 11) in December 2022! Stock will continue to rally into December, and if results are good, I agree with zack'...read more

Third site goes up for MDNA 11 clinical trials

$mdna third clinical site for mdna 11 is now recruiting in Victoria, Australia   https://clinicaltrials.gov/ct2/show/NCT05086692#contacts  rate and reply

MDNA stifel conference today

$mdna at Stifel conference presentation   - Expect to present mdna 11 efficacy data at ASCO June 3, 2022   - MDNA 55 discussions still active and ongoing with several...read more

MDNA reports earnings / good progress on MDNA 11

$mdna December setting up to be huge month of catalysts! Pivotal month. PK/PD for mdna 11 in late December. Assuming that goes well, we will be off to the races as investors build positions for 2022. ...read more

MDNA recent seeking alpha article

Good seeking alpha article summarzing $MDNA opportunity... end of 2021 and year 2022 looking very good for this little stock that could...multi-bagger potential within a year... good time to buy...read more

MDNA CEO insider buying

$MDNA CEO Merchant bought $100K of shares open market recently, avg price $2.15. CFO added a few shares too. Merchant already largest shareholder at 30%+,continues toadd. This is very positive given 9...read more

MDNA tax loss selling pressure

According to Canaccord : in last 5 years, stocks on TSX down more than 15% ytd as of mid-Nov have underperformed the index by almost 4% over the month to mid-Dec and then, in the subsequent month (mid...read more

MDNA competitor NKTR reported earnings

nktr reported earnings yesterday. Stock down 20%+ as market not liking some early data results from ph1/ph2 keytruda combo + their main drug IL-2 BEMPEG NKTR 214 for lung cancer (propel); recall that...read more

mdna added new trial sites

$mdna   Updated: 10/27/2021   3 additional sites have been added in Australia.  Can go to clinical .gov site  Medicenna ability study https://clinicaltrials.gov/ct2/show...read more

Publication of $MDNA 11 (IL-2) study

Publication of $MDNA 11 (IL-2) animal studies, incl non-human primates in the prestigious peer-revieed ASCO today. Title: $MDNA 11 is a long-acting IL-2 superkine that potentiates durable immune...read more

December catalyst two months away!

Not crappin on $nktr, $nltx thor and other il2 players. cancer immuno mkt is huge, there'll be many winners in space not just one. $mdna at $160 mm mkt is the cheapest il2 player with the greatest...read more

mdna too cheap / december topline phase 1 results coming

$mdna We know how $nktr and thor did in their ph1-2 trials.  They both showed NO monotheraphy efficacy.  That's why they are in phase 3 combo trials with checkpoint inhibitors. ...read more

October is upon us!

$mdna October is upon us! We are about two months away from mdna reporting preliminary topline results for potential blockbuster mdna 11. Expect a steady run-up to December, and when mdna shows it'...read more

RE:RE:Clinical Data from Phase 2B Trial

I would say the stock is telling you the franchise drug does not have the needed efficacy to be commercially vuable -do some due dilly for heavens sake -look for the clues   rate and reply